Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.124.321850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Christopher Stone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Brown University, Providence, RI. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Coronary Artery Disease, Coronary Circulation, Ventricular Function, Left. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Coronary artery disease is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy and up to one-thirds with debilitating angina amenable neither to procedures, nor to current pharmacological options. Semaglutide (SEM), a GLP-1 (glucagon-like peptide 1) agonist originally approved for management of diabetes, has garnered substantial attention for its capacity to attenuate cardiovascular risk. Although subgroup analyses in patients indicate promise, studies explicitly designed to isolate the impact of SEM on the sequelae of coronary artery disease, independently of comorbid diabetes or obesity, are lacking. METHODS: Yorkshire swine (n=17) underwent placement of an ameroid constrictor around the left circumflex coronary artery to induce coronary artery disease. Oral SEM was initiated postoperatively at 1.5 mg and scaled up in 2 weeks to 3 mg in treatment animals (n=8) for a total of 5 weeks, while control animals (n=9) received no drug. All then underwent myocardial harvest with acquisition of perfusion and functional data using microsphere injection and pressure-volume loop catheterization. Immunoblotting, immunohistochemistry, and immunofluorescence were performed on the most ischemic myocardial segments for mechanistic elucidation. RESULTS: SEM animals exhibited improved left ventricular ejection fraction, both at rest and during rapid myocardial pacing (both P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Brown University, Providence, RI.
ORCID-Profile: Christopher Stone, Mark Broadwin, Meghamsh Kanuparthy, Ju-Woo Nho, Keertana Yalamanchili, Jad Hamze, M Ruhul Abid, Frank W Sellke
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Stone, C., Harris, D. D., Broadwin, M., Kanuparthy, M., Nho, J. W., Yalamanchili, K., Hamze, J., Abid, M. R., & Sellke, F. W. (2025). Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.321850
Vancouver
Stone C, Harris DD, Broadwin M, Kanuparthy M, Nho JW, Yalamanchili K, et al. Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.321850
BibTeX
@article{Stone2025,
author = {Stone, Christopher and Harris, Dwight D and Broadwin, Mark and Kanuparthy, Meghamsh and Nho, Ju-Woo and Yalamanchili, Keertana and Hamze, Jad and Abid, M Ruhul and Sellke, Frank W},
title = {Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.124.321850}
}
EUVIMED